Helix BioPharma Corp. (TSX:HBP)

Helix BioPharma Balance Sheet

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2025	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Cash & Equivalents	0.5	0.07	1.08	0.81	3.25	3.57
Cash & Short-Term Investments	0.5	0.07	1.08	0.81	3.25	3.57
Cash Growth	118.42%	-93.99%	33.79%	-75.15%	-8.78%	-15.82%
Accounts Receivable	0.04	0.12	0.05	0.06	0.28	0.35
Other Current Assets	0.14	0.22	0.32	0.13	0.16	0.1
Total Current Assets	0.68	0.41	1.46	1	3.7	4.02
Net Property, Plant & Equipment	0	0	0.03	0.03	0.04	0.05
Other Intangible Assets	18.39	18.39	-	-	-	-
Total Assets	19.07	18.8	1.49	1.03	3.73	4.07
Accounts Payable	2.65	2.88	1.58	0.88	0.94	1.47
Accrued Expenses	-	-	-	-	-	0.38
Short-Term Debt	0.35	0.34	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	2.47	2.03
Other Current Liabilities	-	-	-	1	-	-
Total Current Liabilities	3	3.22	1.58	1.87	3.41	3.87
Long-Term Debt	-	-	-	-	-	1.58
Total Long-Term Liabilities	-	-	-	-	-	1.58
Total Liabilities	3	3.22	1.58	1.87	3.41	5.46
Common Stock	180.78	179.29	158.57	152.07	147.51	139.66
Additional Paid-in Capital	52.17	52.17	52.01	48.5	47.93	47.5
Retained Earnings	-216.88	-215.88	-210.67	-201.41	-195.12	-188.55
Total Common Shareholders' Equity	16.07	15.59	-0.09	-0.84	0.32	-1.39
Shareholders' Equity	16.07	15.59	-0.09	-0.84	0.32	-1.39
Total Liabilities & Equity	19.07	18.8	1.49	1.03	3.73	4.07
Total Debt	0.35	0.34	0	0	2.47	3.61
Net Cash (Debt)	0.15	-0.27	1.08	0.81	0.78	-0.05
Net Cash Growth	-	-	33.79%	3.06%	-	-
Book Value	16.07	15.59	-0.09	-0.84	0.32	-1.39
Tangible Book Value	-2.32	-2.8	-0.09	-0.84	0.32	-1.39

Updated Oct 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.